Dr. Pei Dong 董培
Chief Physician
Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of kidney cancer, benign kidney tumors, adrenal tumors, and retroperitoneal tumors. Expertise in minimally invasive (laparoscopic/robotic) nephron-sparing surgery, complex adrenal and retroperitoneal mass resection, and comprehensive management of advanced or metastatic kidney cancer.
Dr. Dong has performed thousands of surgeries for kidney, adrenal, and retroperitoneal tumors, including over 800 da Vinci robotic procedures. Experience includes preoperative risk assessment, neoadjuvant therapy, and nephron-sparing surgery for high-risk kidney cancer. For metastatic kidney cancer, combines drug therapy with local radiotherapy and surgery. Received awards including First Place in the Second South China Urologic Oncology Surgery Video Competition.
Professional roles
- Secretary and Editorial Board Member, Kidney Cancer Diagnosis and Treatment Guideline Writing Group, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Integrated Traditional Chinese and Western Medicine Kidney Cancer Professional Committee, China Anti-Cancer Association (CACA)
- Deputy Leader, Rare Kidney Cancer Collaboration Group, China Anti-Cancer Association (CACA)
- Standing Committee Member, Youth Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Dong Pei). Papers usually list the name as Pei Dong or Dong P.
Selected publications
76 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int Braz J Urol, 2026 (senior author): Tubeless Retroperitoneal Robot-assisted Partial Nephrectomy: An Innovative Approach to Treat Early Renal Tumor. PubMed 42119079
- BMC Med, 2026 (senior author): Camrelizumab plus apatinib for immune checkpoint inhibitor-naive patients with metastatic clear cell renal cell carcinoma after first-line tyrosine kinase inhibitor treatment failure: a single-arm phase 2 trial. PubMed 42026573
- Cancer Immunol Immunother, 2026 (senior author): First-line PD-1 blockades combined with TKIs for metastatic non-clear cell renal cell carcinoma: a real-world multicenter retrospective study. PubMed 41591551
- World J Urol, 2025 (senior author): Clinical effectiveness and safety of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): a single-center retrospective study. PubMed 39903308
- Int Immunopharmacol, 2024 (senior author): Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy. PubMed 39288623
- Clin Genitourin Cancer, 2024 (senior author): Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study. PubMed 38061977
- Int J Cancer, 2023 (senior author): Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. PubMed 35751420
- Clin Cancer Res, 2022 (first author): Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. PubMed 36074152
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion